Corporate Collaborators

Our Corporate Collaborators enable Together 2 Goal® to develop important tools and resources, host provider events, and conduct research and data analysis, among many other campaign-related activities. These special collaborations are an integral part of the campaign’s efforts to provide support to participating groups as we collectively aim to improve care for people with Type 2 diabetes.

Together 2 Goal® Corporate Collaborators include:

Presenting Corporate Collaborator: The Janssen Pharmaceuticals Companies of Johnson & Johnson

The Janssen Pharmaceuticals Companies of Johnson & JohnsonFor Patients with Type 2 diabetes (T2D), Janssen Pharmaceuticals, Inc. offers support in the areas of patient education and patient engagement through the CarePath Healthy Engagements program. This program provides patients with a wide range of resources and tools that focus on topics such as medication adherence, self-management, and more. To view these resources, click here.

Learn more at Follow us at Janssen Pharmaceuticals, Inc. is one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Founding Corporate Collaborator: Novo Nordisk

Novo NordiskNovo Nordisk, a world leader in diabetes care, offers a portfolio of treatments and delivery systems to help improve care for patients.

For more information:

To learn more about Novo Nordisk's tools and resources for managing diabetes, click here.

Distinguished Data and Analytics Corporate Collaborator: Optum

OptumAs a health care services and innovation company, Optum is tackling the biggest challenges in health care by partnering across the entire system. With nearly 125,000 people worldwide, Optum delivers intelligent, integrated solutions that help to modernize the health system and improve overall population health. Optum is part of UnitedHealth Group (NYSE:UNH). For more information, visit

Innovator Track Corporate Collaborator: Boehringer Ingelheim and Eli Lilly and Company

Boehringer Ingelheim LillyIn January 2011, Boehringer Ingelheim and Lilly announced an alliance in diabetes that centers on compounds representing several of the largest diabetes treatment classes. This alliance leverages the strengths of two of the world’s leading pharmaceutical companies. By joining forces, the companies demonstrate commitment in the care of patients with diabetes and stand together to focus on patient needs. Find out more about the alliance at or

In November 2016, Boehringer Ingelheim and Lilly launched a nationwide movement called For Your SweetHeart™: Where diabetes and heart disease meet to raise awareness of the link between type 2 diabetes and heart disease and to encourage people with type 2 diabetes to know their risk and speak to their healthcare provider, for the sake of their health and the people they cherish the most. For more information, visit

Contributing Corporate Collaborator: Merck